Cognitive Therapy, Modafinil, Combo All Beneficial for Multiple Sclerosis Fatigue
By Elana Gotkine HealthDay Reporter
FRIDAY, Oct. 25, 2024 -- Cognitive behavioral therapy (CBT), modafinil, and their combination are equally beneficial for multiple sclerosis fatigue, according to a study published in the November issue of The Lancet Neurology.
Tiffany J. Braley, M.D., from the University of Michigan in Ann Arbor, and colleagues conducted a randomized, comparative effectiveness trial at two universities in the United States to compare CBT, modafinil, and their combination for the treatment of multiple sclerosis fatigue. A total of 336 adults with multiple sclerosis and problematic fatigue were randomly assigned to receive CBT, modafinil, or both for 12 weeks (114, 114, and 108 individuals, respectively).
The researchers found that CBT, modafinil, and combination therapy were associated with clinically meaningful within-group reductions in the Modified Fatigue Impact Scale (MFIS) of 15.20, 16.90, and 17.30 points, respectively, at 12 weeks. From baseline to 12 weeks, the change in MFIS scores did not differ between the groups; the adjusted total mean difference in MFIS change was 1.88 and 1.20 for CBT and modafinil, respectively, relative to the combination group. For modafinil-containing groups, the most common adverse events included insomnia and anxiety.
"Results of this randomized comparative effectiveness research trial of telephone-based CBT, modafinil, and combination therapy suggest that each treatment offers largely equivalent, clinically meaningful benefits for the effects of multiple sclerosis fatigue in people with multiple sclerosis, with high acceptance, good adherence, and good tolerability," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Gabapentin for Back Pain Linked to Increased Risk for Dementia, MCI
FRIDAY, July 11, 2025 -- For adults with chronic low back pain, gabapentin prescription is associated with an increased risk for dementia and mild cognitive impairment (MCI)...
Lead Exposure Linked to Faster Rate of Forgetting Among Children
FRIDAY, July 11, 2025 -- Developmental lead (Pb) exposure is associated with an increased rate of forgetting among children, according to a study published online July 9 in...
Greater Neighborhood Disadvantage Tied to Inflammatory, Alzheimer Disease Biomarkers
THURSDAY, July 3, 2025 -- Greater neighborhood disadvantage is associated with increased inflammatory and Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers in older...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.